No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RNAC240920C5000
- 0.10
- 0.000.00%
15min DelayClose Mar 7 15:22 ET
0.00High0.00Low
0.00Open0.10Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-71.25%PremiumSep 20, 2024Expiry Date12.74Intrinsic Value100Multiplier69DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma177.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Cartesian Therapeutics Announces New Employment Inducement Grants
Express News | Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effecti
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Cartesian Therapeutics, Inc. (RNAC) announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis (MG), an autoimmune disease associated with muscle weakness.
Cartesian Therapeutics Price Target Cut to $49.00/Share From $54.00 by HC Wainwright & Co.
Cartesian Therapeutics Price Target Cut to $49.00/Share From $54.00 by HC Wainwright & Co.
Syncona Board Member Takes Role at Cartesian Therapeutics
Comments
$Cartesian Therapeutics(RNAC.US$ Press Release: Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Dow Jones· just
Dow Jones· just
2
$Cartesian Therapeutics(RNAC.US$Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Murat Kalayoglu(19.9%),Seven One Eight Three Four Irrevocable Trust(17.1%), etc.
SEC announcement
13 mins ago
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals...
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Murat Kalayoglu(19.9%),Seven One Eight Three Four Irrevocable Trust(17.1%), etc.
SEC announcement
13 mins ago
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals...
1
7
$Cartesian Therapeutics(RNAC.US$ did no one notice springer just bought another 1.9million shares just today 👀, simply does not explain the price action point for this week at all. Eccentric !
$Cartesian Therapeutics(RNAC.US$ FMR had a top position in Viking Therapeutics, and here in Cartesian as well. The reverse split is to allow more institutions to follow suit. If you were to read the paper closely on the pipeline, their RNA cell therapy extends to a suite of autoimmune diseases. With a production up and coming, more partnership might be announced very soon.
$Cartesian Therapeutics(RNAC.US$ there is 50 million shares buy-in (pending) from institutions, CRISPP recently shifted their interest on cell therapy as well, speak volume in the position that Cartesian is in.
Read more
andy(三叔） : $Chicken Soup for the Soul Entertainment (CSSE.US)$ $Chicken Soup For The Soul Entmt Inc 9.50% Notes Due 2025 Usd25 (CSSEN.US)$ $Chicken Soup for the Soul Entertainment Inc (CSSEP.US)$
TrytosaveabitOP andy(三叔）: It’s a bankruptcy play from Redbox filing for protection!